


DiogenX raises €27.5M Series A financing to advance its first-in-class regenerative treatment for type 1 diabetes towards clinical development

ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)

French biotech Calida Therapeutics launches with seed funding, leveraging US academic research in thrombo-inflammatory disorders
